AIDS Therapies

Combination Sustiva (Efavirenz) + AZT, or 3TC Clinical Results Reported

Published in AIDS Weekly, October 27th, 1997

The DuPont Merck Pharmaceutical Company, Wilmington, Delaware, announced that Sustiva (efavirenz), its once-daily investigational anti-HIV medicine, has shown significant viral load reduction in patients receiving combination therapy not involving a protease inhibitor.

Most triple combination therapy to date involves protease inhibitors. Sustiva, also called efavirenz or DMP 266, is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which, in this trial, is being studied in combination with Retrovir (zidovudine, AZT) and Epivir (lamivudine, 3TC) to treat HIV and AIDS. These findings were presented as part of the current Sixth European Conference on Clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry